Disease Modification in Severe Asthma: Reality or Utopia

This content is sponsored by GSK and is intended for healthcare professionals only.

Prescribing information for Nucala (mepolizumab) can be found here. Adverse Event reporting information can be found at the bottom of this page.

Scientific dissemination is based on published and accessible data and has an informative/educational purpose for healthcare professionals. To this end, the data are presented faithfully reflecting scientific publications without any modification or addition. Its content is protected by copyright and cannot be reproduced (photo, recording or “screenshots”), nor disclosed or transmitted to any third party by any means without the written authorisation of GSK.

In this interactive webinar, leading experts will examine whether disease modification in severe asthma is an achievable reality or remains a distant goal. The discussion will explore the evolving objectives of asthma management, from symptom relief to long-term disease control, and the potential for clinical remission through early intervention with biologics. Speakers will address key barriers to remission, including comorbidities, corticosteroid toxicity, and delayed treatment, and highlight the importance of individualised, multidimensional approaches. Finally, the session will consider the role of airway remodelling and Type 2 inflammation in disease progression, evaluating whether biologic therapies could alter the natural course of severe asthma. 

1. Careggi University Hospital in Florence, Italy
2. University of Rostock, Germany
3. University Hospital Southampton, UK
4. University of Southampton, UK 

Disclosures:

Vultaggio has been an advisor or speaker and received grants/research support from: ALK, Astra Zeneca, Bencard, GSK, Novartis, Sanofi-Genzyme, Stallergenes-Greer; and has been on advisory boards and received payments/honoraria for lectures from AstraZeneca, GSK, Sanofi, and Novartis.

Virchow has given independent lectures for and received honoraria from: ALK-Abello, Allergopharma, AstraZeneca, Avontec, Bayer, Bencard, Bionorica, Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, Leti, MEDA, Merck, MSD, Mundipharma, Novartis, Nycomed/Altana, Pfizer, Revotar, Sandoz-Hexal, Stallergens, TEVA, UCB/Schwarz-Pharma, Zydus/Cadila and possibly others; been on advisory boards and provided independent advice for ALK-Abello, Allergopharma, Avontec, Boehringer-Ingelheim, Chiesi, Essex/Schering-Plough, GSK, Janssen-Cilag, MEDA, MSD, Mundipharma, Novartis, Regeneron, Revotar, Roche, Sanofi-Aventis, Sandoz-Hexal, TEVA, UCB/Schwarz-Pharma and possibly others; received research grants from: Deutsche Forschungsgesellschaft, Land Mecklenburg-Vorpommern, GSK, MSD.

Rupani has received speaker and consultancy fees from AstraZeneca, GlaxoSmithKline, Teva, Novartis, and Chiesi; and has a research grant funded by GlaxoSmithKline.